Visiongain has published a new report entitled Precision Medicine Market Report 2025-2035: Forecasts by Product (Therapeutics (Monoclonal Antibodies, Inhibitor Drugs, Cell & Gene Therapies, RNA-Based Therapies, Others), Diagnostics (Genetic Tests, Biomarker-based Tests, Other)), by Application (Oncology, Immunology, CNS, Respiratory, Others), by Technology (Gene Sequencing, Drug Discovery, Big Data Analytics, Companion Diagnostics, Bioinformatics, Other), by End-users (Hospitals, Diagnostic Centres, Research & Academic Institutes, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies.

The global precision medicine market is estimated at US$157.76 billion in 2025 and is projected to grow at a CAGR of 15.1% during the forecast period 2025-2035.

Impact of US Trade Tariffs on the Global Precision Medicine Market   

The U.S. trade tariffs have introduced notable disruptions in the global precision medicine market by increasing the cost of importing essential raw materials, laboratory reagents, diagnostic equipment, and biotechnological components. Many of these products are sourced from countries affected by tariffs, such as China and other Asian economies, which has caused an uptick in production expenses for pharmaceutical and diagnostic companies. As precision medicine relies heavily on cutting-edge technology and high-quality, often imported components, the tariffs have put pressure on both multinational corporations and smaller biotech startups. 

For smaller firms with limited budgets and narrow profit margins, absorbing these additional costs is particularly difficult, often forcing them to scale back research efforts or delay product development. In addition to raising costs, the tariffs have indirectly slowed innovation in precision medicine by disrupting global supply chains and cross-border research collaborations. Many U.S.-based companies are now reconsidering their manufacturing and sourcing strategies, exploring options to localise production or partner with suppliers in non-tariffed countries. However, transitioning supply chains is time-consuming and costly, especially in an industry where regulatory compliance and product quality are of paramount importance. Furthermore, the uncertainty surrounding ongoing trade negotiations adds another layer of complexity, making it harder for businesses to plan long-term investments in precision medicine infrastructure and development.

Growing Biopharmaceutical Research, Regulatory Support, and Innovation in the Biopharmaceutical Sector

The reach and impact of personalised medicine are set to expand even further in the years ahead with biopharmaceutical research, regulatory encouragement, and innovation from the biopharmaceutical sector. Several recent milestones illustrate this evolution. On 23 October 2024, the U.S. National Cancer Institute launched myeloMATCH. It is a clinical trial focused on customising treatments for patients with myelodysplastic syndromes and acute myeloid leukaemia through genetic profiling. In another key development, the U.S. FDA expanded the approval of Amvuttra, an RNA interference (RNAi) therapy developed by Alnylam Pharmaceuticals, on March 20, 2025, for treating cardiomyopathy related to transthyretin-mediated amyloidosis (ATTR-CM), a previously underserved condition in cardiology. Additionally, on January 25, 2025, the UK’s National Health Service (NHS) began using liquid biopsy techniques in breast cancer care, allowing clinicians to detect ESR1 mutations and prescribe personalized treatments like elacestrant.

How will this Report Benefit you?

Visiongain’s 463-page report provides 187 tables, 293 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analysis for the precision medicine market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for precision medicine. Get financial analysis of the overall market and different segments including product, application, technology, end-user, and capture higher market share. We believe that there are strong opportunities in this fast-growing precision medicine market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the Current Market Drivers?

Increasing Demand for Targeted Therapies 

The increasing demand for targeted therapies is a key driver behind the growth of the precision medicine market, as healthcare continues to move toward more personalised, effective, and less harmful treatment approaches. These therapies specifically target molecular markers associated with diseases, minimising damage to healthy cells and enhancing patient outcomes. For instance, on January 16, 2025, the FDA granted traditional approval for Calquence (acalabrutinib) in combination with bendamustine and rituximab for treating mantle cell lymphoma (MCL). Similarly, on March 26, 2025, Bayer entered a licensing agreement for a PRMT5inhibitor targeting MTAP-deleted tumors, marking another step forward in cancer precision medicine. This trend is gaining momentum due to the rising prevalence of cancer, genetic disorders, and chronic illnesses, where biomarker-based treatments and companion diagnostics are making a significant impact. Consequently, pharmaceutical companies and research organizations are accelerating investments in precision therapies designed to match individual genetic profiles.

Rising Adoption of Precision Medicine

The medical landscape is clearly transitioning from conventional, generalized treatments to precision medicine, which emphasizes therapies tailored to a patient’s genetic makeup. This approach aims to improve treatment effectiveness while minimizing side effects. By utilizing genomic profiling, targeted drug delivery, and biomarker-driven diagnostics, precision medicine is enabling more personalized and accurate care. This shift is becoming increasingly prominent across multiple areas, including oncology, infectious diseases, and advanced imaging-based diagnostics.

On March 25, 2025, the FDA approved Blujepa (gepotidacin), an antibiotic for urinary tract infections (UTIs) that specifically targets antibiotic-resistant bacterial strains, marking a shift from broad-spectrum antibiotics to precision-based infection treatment. Moreover, on March 21 2025, Telix Pharmaceuticals received FDA approval for Gozellix, a prostate cancer imaging agent, enhancing the accuracy of PSMA-positive lesion detection and aiding in personalized treatment planning. These advancements highlight how precision medicine is replacing conventional approaches, ensuring more effective, targeted, and patient-centric treatments. As genomic sequencing, AI-driven diagnostics, and biomarker-driven drug development continue to progress, precision medicine is set to become the new standard of care across multiple disease areas.

Where are the Market Opportunities?

Growing Acceptance of Gene Therapy and Gene Editing Technologies

The growing acceptance of gene therapy and gene editing technologies is reshaping how genetic disorders, rare diseases, and chronic conditions are treated. Innovations in CRISPR, viral vector delivery, and cell-based therapies are enhancing both the safety and effectiveness of these approaches, encouraging broader adoption. As a result, more pharmaceutical companies and healthcare providers are channelling resources into this space. Supportive regulatory approvals and increased funding are also accelerating progress, positioning gene therapies as a crucial component of the evolving precision medicine landscape. On March 20, 2025, Bharat Biotech revealed plans to invest US$75 million in establishing its inaugural cell and gene therapy facility in Telangana, India. On January 31, 2025, the UK’s NHS introduced a CRISPR-based gene therapy for sickle cell disease, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, providing treatment to 50 patients annually at £1.65 million (US$2.2 million) per procedure. These examples highlight the rapid evolution of gene therapy, as increased funding, regulatory approvals, and breakthrough research drive its integration into mainstream healthcare. 

Competitive Landscape

The major players operating in the precision medicine market are 23andMe, Inc., Abbott, Abnova Corporation, Adaptive Biotechnologies, Agilent Technologies Inc., AstraZeneca, Bayer AG, Biogen, bioMérieux SA, Bristol-Myers Squibb Company, Bruker Corporation, Danaher, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GE HealthCare, GRAIL Inc., GSK plc, Illumina, Inc., Johnson & Johnson, Laboratory Corporation of America Holdings, Myriad Genetics Inc., Novartis AG, Pfizer Inc., Qiagen, Quest Diagnostics Incorporated, Regeneron Pharmaceuticals, Tempus, and Teva Pharmaceutical Industries Ltd. Leading companies in the precision medicine market are actively pursuing strategies such as mergers and acquisitions, strategic collaborations, increased R&D investment, regional expansion, partnerships, and the launch of innovative products. These approaches are aimed at strengthening their market position, enhancing technological capabilities, and meeting the growing demand for personalized healthcare solutions.

Recent Developments

• On 12^th February 2025, The U.S. Food and Drug Administration (FDA) approved Pfizer’s ADCETRIS combination regimen for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
• On 27^th January 2025, Quest Diagnostics, a prominent provider of diagnostic information services, officially concluded the acquisition of certain assets from University Hospitals, a distinguished nonprofit health system and academic medical center in the U.S. 
• On 7^th January 2025, Qiagen reported collaboration with Genomics England to aid in the rollout of the Generation Study. This groundbreaking project seeks to sequence the genomes of 100,000 newborns in England, enabling the early detection of more than 200 specific conditions and supporting timely diagnosis and treatment of rare diseases.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to contactus@visiongain.com or call +44 207 336 6100.

About Visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.